MY173117A - Vaccine composition comprising an inactivated chikungunya virus strain - Google Patents

Vaccine composition comprising an inactivated chikungunya virus strain

Info

Publication number
MY173117A
MY173117A MYPI2013004491A MYPI2013004491A MY173117A MY 173117 A MY173117 A MY 173117A MY PI2013004491 A MYPI2013004491 A MY PI2013004491A MY PI2013004491 A MYPI2013004491 A MY PI2013004491A MY 173117 A MY173117 A MY 173117A
Authority
MY
Malaysia
Prior art keywords
vaccine composition
virus strain
chikungunya virus
inactivated
inactivated chikungunya
Prior art date
Application number
MYPI2013004491A
Other languages
English (en)
Inventor
Krishna Murthy Ella
Sumathy Kandaswamy
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of MY173117A publication Critical patent/MY173117A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MYPI2013004491A 2011-06-17 2012-06-18 Vaccine composition comprising an inactivated chikungunya virus strain MY173117A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2067CH2011 2011-06-17
PCT/IN2012/000432 WO2012172574A1 (en) 2011-06-17 2012-06-18 Vaccine composition comprising an inactivated chikungunya virus strain

Publications (1)

Publication Number Publication Date
MY173117A true MY173117A (en) 2019-12-27

Family

ID=46601866

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013004491A MY173117A (en) 2011-06-17 2012-06-18 Vaccine composition comprising an inactivated chikungunya virus strain

Country Status (12)

Country Link
US (1) US9844588B2 (enExample)
EP (1) EP2720715B1 (enExample)
JP (1) JP6147734B2 (enExample)
KR (1) KR101792684B1 (enExample)
CN (1) CN103796676B (enExample)
AU (1) AU2012269907B2 (enExample)
BR (1) BR112013032251B1 (enExample)
MY (1) MY173117A (enExample)
PH (1) PH12013502621A1 (enExample)
SG (1) SG10201607787RA (enExample)
WO (1) WO2012172574A1 (enExample)
ZA (1) ZA201309386B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357202B (es) * 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
TWI676636B (zh) 2013-07-12 2019-11-11 Vlp醫療股份有限公司 包含pd-1抗原或pd-1配體抗原的類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI720946B (zh) 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
CA2992531C (en) * 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
US20190054161A1 (en) * 2016-01-13 2019-02-21 United States, As Represented By The Secretary Of The Army Inactivated vaccine for chikungunya virus
CN105906694B (zh) * 2016-05-05 2019-05-14 中国人民解放军军事医学科学院微生物流行病研究所 基孔肯亚病毒特异性检测抗原及其应用
PH12018502460B1 (en) * 2016-05-27 2023-11-08 Univ Griffith Arthrogenic alphavirus vaccine
KR101875055B1 (ko) * 2016-10-19 2018-07-06 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
KR102007203B1 (ko) * 2016-10-20 2019-08-05 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
WO2018074884A1 (ko) * 2016-10-20 2018-04-26 연세대학교 원주산학협력단 재조합 단백질 및 그의 용도
CN118662621A (zh) * 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003975WA (en) 2017-11-30 2020-06-29 Takeda Vaccines Inc Method for inactivating zika virus and related methods
KR102823029B1 (ko) 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
WO2019148086A1 (en) * 2018-01-26 2019-08-01 The Wistar Institute Of Anatomy And Biology Vaccines against mosquito-borne viruses, and methods of using same
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
KR102016668B1 (ko) 2018-12-19 2019-08-30 주식회사 엠디헬스케어 치쿤군야 바이러스 e2에 특이적으로 결합하는 dna 압타머 및 이의 용도
US11562105B2 (en) * 2019-07-11 2023-01-24 Yokogawa Electric Corporation System and method for module engineering with sequence libraries
KR102202082B1 (ko) 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
TWI891771B (zh) 2020-04-17 2025-08-01 美商Vlp醫療股份有限公司 冠狀病毒疫苗
MX2022013638A (es) 2020-04-30 2023-01-24 Vlp Therapeutics Inc Inmunoterapia con citocina.
AU2021315795A1 (en) * 2020-07-31 2023-02-23 Replicate Bioscience, Inc. Modified Chikungunya viruses and Sindbis viruses and uses thereof
CN117771353B (zh) * 2024-02-27 2024-05-14 中国医学科学院医学生物学研究所 一种以包膜蛋白为靶标的基孔肯雅病毒的mRNA疫苗及其制备方法
CN118561969B (zh) * 2024-08-02 2024-11-19 中国医学科学院医学生物学研究所 一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233209A1 (en) * 2005-08-11 2010-09-16 Higgs Stephen T Chikungunya virus infectious clones and uses therefor
BRPI0716145B1 (pt) 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
JP2009149583A (ja) * 2007-12-21 2009-07-09 National Institute Of Biomedical Innovation フラビウイルス感染症ワクチンおよびフラビウイルス感染症ワクチン用アジュバント
CN102317308A (zh) 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法

Also Published As

Publication number Publication date
PH12013502621A1 (en) 2014-02-03
CN103796676B (zh) 2017-09-12
US20140120125A1 (en) 2014-05-01
WO2012172574A1 (en) 2012-12-20
KR101792684B1 (ko) 2017-11-02
BR112013032251A2 (pt) 2016-12-20
US9844588B2 (en) 2017-12-19
KR20140043784A (ko) 2014-04-10
SG10201607787RA (en) 2016-11-29
ZA201309386B (en) 2014-08-27
BR112013032251B1 (pt) 2021-12-07
AU2012269907B2 (en) 2017-05-18
JP6147734B2 (ja) 2017-06-14
CN103796676A (zh) 2014-05-14
JP2014520117A (ja) 2014-08-21
AU2012269907A1 (en) 2014-01-09
EP2720715A1 (en) 2014-04-23
EP2720715B1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
ZA201309386B (en) Vaccine composition comprising an inactivated chikungunya virus strain
IL229307A0 (en) Inactivated dengue virus vaccine
IL235890A0 (en) vaccine
ZA201404797B (en) Influenza virus vaccines and uses thereof
SG11201400743VA (en) Influenza virus vaccines and uses thereof
GB201223386D0 (en) Vaccine
ZA201300395B (en) Influenza vaccine
SG10201912291YA (en) Vaccine compositions
PT3072979T (pt) Estirpe de methanothermobacter thermautotrophicus e suas variantes
IL222228A0 (en) Hiv vaccine
AU2012307348A8 (en) Vaccine
SI2931304T1 (sl) Cepivo proti WT1
GB201119999D0 (en) Vaccine
SG11201502221WA (en) Novel attenuated dengue virus strains for vaccine application
EP2667891A1 (en) Combination vaccines
ZA201404512B (en) Malaria vaccine
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201120000D0 (en) Vaccine
GB201202090D0 (en) Vaccine
AU2013369626A1 (en) Dengue virus vaccine composition
SG11201505170WA (en) Dengue virus vaccine composition
ZA201302154B (en) Vaccine
HK1192850A (en) Inactivated dengue virus vaccine